



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/43, 47/12		A1	(11) International Publication Number: WO 93/00898 (43) International Publication Date: 21 January 1993 (21.01.93)
(21) International Application Number: PCT/GB92/01207 (22) International Filing Date: 3 July 1992 (03.07.92)		(74) Agents: WALKER, Ralph, Francis et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).	
(30) Priority data: 9114950.0 11 July 1991 (11.07.91) GB		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).	
(71) Applicant (<i>for all designated States except US</i>): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): CLAPHAM, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB).		Published <i>With international search report.</i>	
<p>(54) Title: PHARMACEUTICAL FORMULATION OF A BETA-LACTAM ANTIBIOTIC AND CLAVULANIC ACID OR A WATER-SOLUBLE SALT THEREOF</p> <p>(57) Abstract</p> <p>A pharmaceutical formulation comprising one or more β-lactam antibiotics, clavulanic acid or a water-soluble salt thereof, a pharmaceutically acceptable dicarboxylic acid, and a salt of the dicarboxylic acid in which both acidic hydrogen atoms are replaced by a cation.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

PHARMACEUTICAL FORMULATION OF A BETA-LACTAM ANTIBIOTIC AND CLAVULANIC ACID OR A WATER SOLUBLE SALT THEREOF

This invention relates to pharmaceutical formulations, in particular to formulations containing β -lactam antibiotics and the β -lactamase inhibitor

- 5 clavulanic acid or derivatives thereof, especially aqueous suspension formulations.

Pharmaceutical formulations containing a β -lactam antibiotic and clavulanic acid or derivatives such as its salts are known. Clavulanic acid
10 in aqueous suspension or solution is known to suffer to some extent from instability, and one significant determinant of stability is the pH of the aqueous medium of the suspension or solution, pH 5.8 - 6.2 being known to be the optimum.

- 15 At present the pH of pharmaceutical formulations containing clavulanic acid in suspension or solution is modified by including succinic acid in the formulation. Attempts have been made to further control the pH by the use of buffer salts, but it is found that many commonly used pharmaceutically acceptable buffer salts such as phosphate, citrate,
20 carbonate etc have a catalytic effect deleterious to the stability of the clavulanic acid, and moreover the increased ionic strength of the suspension is also believed to be deleterious to clavulanic acid stability.

- 25 This invention provides novel improved pharmaceutical formulations containing clavulanic acid or derivatives thereof in which these problems have to some extent been alleviated, and further unexpected advantages have been achieved.

- 30 Accordingly the invention provides a pharmaceutical formulation comprising;

one or more β -lactam antibiotics;

clavulanic acid or a water-soluble salt thereof;

- 35 a pharmaceutically acceptable dicarboxylic acid, and;

a salt of the dicarboxylic acid in which both acidic hydrogen atoms are

replaced by a cation.

The formulation may be an aqueous suspension or solution formulation, eg for oral administration or may alternatively be a dry powder, granular

5 or tablet formulation provided primarily for reconstitution into an aqueous suspension or solution formulation.

The one or more β -lactam antibiotics may be penicillins or cephalosporins, especially amoxycillin and ampicillin, preferably amoxycillin in the form

10 of its trihydrate. The clavulanic acid is preferably in the form of one of its salts with a pharmaceutically acceptable cation, especially potassium clavulanate.

Typically the weight ratio of antibiotic: clavulanic acid or clavulanate

15 anion equivalent is in the range 12 : 1 to 1 : 1, suitably 8 : 1 to 1.5 : 1. In an aqueous suspension or solution formulation the concentration of antibiotic and clavulanic acid or clavulanate equivalent will vary depending upon the size of the unit dose in which it is intended to be administered. Typically formulations for oral administration are

20 administered in unit doses of around 5ml spoonfuls or as paediatric drops for small children. Typically the total combined concentration of antibiotic and clavulanic acid or equivalent in such suspensions or solutions may be in the range 25 - 250 mg/ml, for example 30-125 mg/ml. When the formulation is in the form of dry powder, granules or tablets for

25 reconstitution the quantity of antibiotic and clavulanic acid or equivalent may be derived accordingly.

Typical pharmaceutically acceptable dicarboxylic acids are those having a general formula HOOC.(CH₂)_nCOOH wherein n is 1-6 and in which two

30 adjacent (CH₂) groups may be replaced by CH=CH, for example succinic acid, malonic acid, maleic acid and fumaric acid. Of these succinic acid is preferred.

The dicarboxylic acid salt, eg. a succinic acid salt may be of a divalent

35 cation such as calcium or other pharmaceutically acceptable cation, eg of a Group II metal, in which case a single such cation may replace both of the acidic hydrogen atoms. Alternatively each acidic hydrogen atom may be replaced by a monovalent cation such as sodium, potassium or other

- 3 -

pharmaceutically acceptable monovalent cation. Disodium succinate is preferred on account of its low cost, used in combination with succinic acid.

- 5 Typically the weight ratio of succinic acid : disodium succinate may be in the range 1 : 50 to 1 : 0.05 representing a molar ratio of succinic acid : succinic acid salt in the range 1 : 33 to 3 : 1. Suitable weight ratios of succinic acid : disodium succinate are around 1 : 30 to 1 : 15, for example 1 : 19 ± 1. Typical weight ranges for other salts may be calculated from
10 these ranges on the basis of the corresponding weight of succinate anion. Typically in an aqueous suspension or solution formulation the total molarity of succinic acid and succinate salt may be in the range 0.001M to 0.01M, suitably 0.001M to 0.0052 M, for example 0.005 ± 0.0001 M. When the formulation is in the form of dry powder, granules or tablets for
15 reconstitution the quantity of succinic acid and succinate salt may be derived accordingly.

- The formulation may also optionally contain excipients which may be essentially conventional in the art. For example aqueous suspension or
20 solution formulations may typically contain suspending agents such as Xantham gum, for example 0.25-5 mg/ml, suitably 0.5 - 2.5 mg/ml, thickening agents such as cellulose derivatives, for example 1 - 100 mg/ml if present, sweeteners such as aspartame or equivalent sugars, eg 0.5-5 mg/ml, and flavouring agents such as fruit flavourings and syrup
25 flavourings, eg 10-20 mg/ml etc. Silicas such as "Aerosil" may be present as thickening agents and/or as a powder flow aid, and other silicas such as "Sylloid" may be present as an internal dessicant and bulking agent. Typically silicas may be present at eg 1-100 mg/ml. Dry powder, granule or tablet formulations for reconstitution may contain corresponding
30 weights of these and/or other conventional excipients.

- Aqueous suspension and solution formulations of this invention may be provided in entirely conventional bottles etc, and dry powder or granule formulations for reconstitution may be provided in conventional jars,
35 sachets etc which are advisedly airtight.

The formulations of the invention appear to offer a number of advantages over known formulations which contain a β-lactam antibiotic in

- 4 -

combination with clavulanic acid or clavulanate equivalent. These include improvement of stability in solution for example by 2-4% of the initial concentration on storage for 7 days at 5°C. The stability in solution is more robust in terms of pH differences in the water used to make up the
5 suspension or solution and the quality of raw materials such as amoxycillin trihydrate. The presence of succinate ion appears to inhibit the colour change from white to pale cream that sometimes follows reconstitution, and there appears to be some enhancement of the flavour of reconstituted suspensions and solutions.

10

The invention also provides a process for the preparation of such a pharmaceutical formulation, comprising admixing the β -lactam antibiotic, the clavulanic acid or salt thereof, the dicarboxylic acid and the salt thereof, and optionally any excipients, and optionally making the product
15 up with water or an aqueous medium to form a suspension or solution formulation.

The invention also provides a process for the use of a pharmaceutical formulation as described above in the manufacture of a medicament for
20 the treatment of bacterial infections.

The invention also provides a pharmaceutical formulation as described above for use in the treatment of bacterial infections.

25 The invention also provides a method of treatment of bacterial infections in humans or animals which comprises the administration of a therapeutically effective amount of a pharmaceutical formulation as described above.

30 The invention will now be described by way of example only. In these examples the abbreviation (fa) as used in connection with amoxycillin trihydrate and potassium clavulanate indicates that the weight is expressed as the equivalent of free acid, ie respectively amoxycillin and clavulanic acid.

35

- 5 -

Example 1

Amoxycillin/Clavulanate Suspension

<u>Ingredient</u>	<u>mg per 100ml</u>
Amoxycillin trihydrate	2500.0 (fa)
Potassium clavulanate	656.25 (fa)
Xanthan gam (Keltrol T)	250.0
Aspartame	250.0
Colloidal silica (Aerosil 200)	500.0
Silicon dioxide (Sylloid ALI)	2500.0
Methocel E5	3000.0
Succinic acid	2.95
Disodium succinate	76.97
Raspberry dry flavour (Naarden)	450.0
Orange dry flavour (P.F.W.)	300.0
Orange dry flavour (Dragoco)	225.0
Golden syrup flavour (Fermenich)	475.0

5

A unit dose of 5ml of this suspension contains 156 mg of amoxycillin/clavulanic acid combination.

- 6 -

Example 2

Amoxycillin/Clavulanate Suspension (Paediatric Drops)

<u>Ingredient</u>	<u>mg per 30 ml</u>
Amoxycillin trihydrate	3000.0 (fa)
Potassium clavulanate	393.75 (fa)
Xanthan gam (Keltrol T)	50.0
Aspartame	75.0
Colloidal silica (Aerosil 200)	75.0
Silicon dioxide (Sylloid ALI)	750.0
Succinic acid	1.0
Disodium succinate (Anhydrous)	23.1
Raspberry dry flavour (Naarden)	135.0
Orange dry flavour (P.F.W.)	90.0
Orange dry flavour (Dragoco)	67.5
Golden syrup Dry flavour (Fermenich)	143.0

5

This suspension contains 112.5 mg per ml of amoxycillin/clavulanic acid combination.

Example 3Amoxycillin/Clavulanate Suspension

<u>Ingredient</u>	<u>mg per 100 ml</u>
Amoxycillin trihydrate	5000.0 (fa)
Potassium clavulanate	1312.5 (fa)
Xanthan gum (Keltrol T)	250.0
Aspartame	250.0
Colloidal silica (Aerosil 200)	500.0
Silicon dioxide (Syloid ALI)	2500.0
Methocel E5	3000.0
Succinic acid	2.95
Disodium succinate	76.97
Raspberry dry flavour (Naarden)	450.0
Orange dry flavour (P.F.W.)	300.0
Orange dry flavour (Dragoco)	225.0
Golden syrup flavour (Fermenich)	475.0

5

A unit dose of 5 ml of this suspension contains 312 mg of amoxycillin/clavulanic acid combination.

- 10 The above three suspensions were made up in an entirely conventional manner by adding the ingredients to cold water and stirring. Shaking of the reconstituted suspension immediately prior to administration was found to be desirable to ensure resuspension.

- 8 -

Example 4

Amoxycillin/Clavulanate Suspension

<u>Ingredient</u>	<u>mg per 100ml</u>
Amoxycillin trihydrate	2500.0 (fa)
Potassium clavulanate	1312.5 (fa)
Xanthan gum (Keltrol T)	250.0
Aspartame	250.0
Colloidal silica (Aerosil 200)	500.0
Silicon dioxide (Syloid ALI)	2500.0
Methocel E5	3000.0
Succinic acid	2.95
Disodium succinate	76.97
Raspberry dry flavour (Naarden)	450.0
Orange dry flavour (P.F.W.)	300.0
Orange dry flavour (Dragoco)	225.0
Golden syrup flavour (Fermenich)	475.0

5

A unit dose of 5ml of this suspension contains 187 mg of amoxycillin/clavulanic acid combination.

Claims

1. A pharmaceutical formulation comprising:
one or more β -lactam antibiotics;
clavulanic acid or a water-soluble salt thereof;
a pharmaceutically acceptable dicarboxylic acid, and;
a salt of the dicarboxylic acid in which both acidic hydrogen atoms are replaced by a cation.
2. A pharmaceutical formulation according to claim 1 wherein the β -lactam antibiotic is amoxycillin or ampicillin.
3. A pharmaceutical formulation according to claim 1 or 2 wherein the clavulanic acid is in the form of potassium clavulanate.
4. A pharmaceutical formulation according to any one of the preceding claims wherein the ratio of antibiotic : clavulanic acid is in the range 12 : 1 to 1 : 1.
5. A pharmaceutical formulation according to any one of the preceding claims wherein the dicarboxylic acid has a general formula $\text{HOOC}(\text{CH}_2)_n\text{COOH}$ wherein n is 1-6 and in which two adjacent (CH_2) groups may be replaced by $\text{CH} = \text{CH}$.
6. A pharmaceutical formulation according to claim 5 wherein the dicarboxylic acid is selected from succinic acid, maleic acid, malonic acid and fumaric acid.
7. A pharmaceutical formulation according to any one of the preceding claims wherein the dicarboxylic acid salt is of a divalent cation which replaces both acidic hydrogen atoms.
8. A pharmaceutical formulation according to any one of claims 1-6 in which in the salt of the dicarboxylic acid each acidic hydrogen atom is replaced by a single monovalent cation.
9. A pharmaceutical formulation according to claim 8 wherein the salt of the dicarboxylic acid is disodium succinate.

- 10 -

10. A pharmaceutical formulation according to claim 9 wherein the molar ratio succinic acid : disodium succinate is in the range 1 : 33 to 3 : 1.
11. A pharmaceutical formulation according to claim 9 or 10 being an aqueous solution or suspension and having a total molarity of succinic acid and succinate salt in the range 0.001M to 0.01M.
12. A pharmaceutical formulation according to any one of the preceding claims substantially as hereinbefore described with reference to examples 1 to 4.
13. A process for the preparation of a pharmaceutical formulation as claimed in any one of claims 1 to 12, comprising admixing the β -lactam antibiotic, the clavulanic acid or salt thereof, the dicarboxylic acid and the salt thereof, and optionally any excipients, and optionally making the product up with water or an aqueous medium to form a suspension or solution formulation.
14. A process for the use of a pharmaceutical formulation as claimed in any one of claims 1 to 12 in the manufacture of a medicament for the treatment of bacterial infections.
15. A pharmaceutical formulation as claimed in any one of claims 1 to 12 for use in the treatment of bacterial infections.
16. A method of treatment of bacterial infections in humans or animals which comprises the administration of a therapeutically effective amount of a pharmaceutical formulation as claimed in any one of claims 1 to 12.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/01207

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 A61K31/43; A61K47/12

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.C1. 5	A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A,P	WO,A,9 115 197 (BEECHAM GROUPE PLC) 17 October 1991 see claims 1,2,11 -----	1-16
A	EP,A,0 080 862 (BEECHAM GROUP PLC) 8 June 1983 see page 2; example 1 -----	1-16

* Special categories of cited documents :¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

05 OCTOBER 1992

Date of Mailing of this International Search Report

20.10.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

LEONETTE L. GARNIER

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201207
SA 61585

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file en
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 05/10/92

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO-A-9115197	17-10-91	AU-A-	7558691	30-10-91
EP-A-0080862	08-06-83	AU-A- JP-C- JP-B- JP-A-	9103782 1580055 2006332 58109419	09-06-83 13-09-90 08-02-90 29-06-83